AI-Driven Detection of Ovarian Cancer Surpasses Human Expert-Level Accuracy
THURSDAY, Jan. 9, 2025 (HealthDay News) — Transformer-based neural network models exhibit...
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 1 - 20 of 1482 results for 'ovarian cancer'
Circulating tumor DNA detection improves relapse prediction in epithelial ovarian cancer.
Epithelial ovarian cancer (EOC) is a lethal form of gynecological malignancy. Some EOC patients experience relapse after standard primary debulking surgery (PDS) and adjuvant chemotherapy (ACT). Identifying molecular residual...
Read More
BRCA Reversion Mutations and Olaparib Efficacy in Relapsed Ovarian Cancer
The following is a summary of “Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients...
Read More
Ultrasound Predicts Resectability in Tubo-Ovarian Cancer Comparable to CT and MRI
The following is a summary of “Prediction of nonresectability using the updated Predictive Index...
Read More
Doublet Maintenance Therapy Does Not Outperform Monotherapy in Ovarian Cancer
Adding nivolumab to rucaparib maintenance therapy did not improve progression-free survival rates in patients with ovarian cancer.
Read MoreTargeting the SPC25/RIOK1/MYH9 Axis to Overcome Tumor Stemness and Platinum Resistance in Epithelial Ovarian Cancer.
In epithelial ovarian cancer (EOC), platinum resistance, potentially mediated by cancer stem cells (CSCs), often leads to relapse and treatment failure. Here, the role of spindle pole body component 25 (SPC25) as a key...
Read More
IOTA ADNEX at 10 Percent Has Higher Sensitivity for Ovarian Cancer
WEDNESDAY, Oct. 16, 2024 (HealthDay News) — The International Ovarian Tumour Analysis...
Read MorePrognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer.
To determine the prognostic impact of microscopic residual disease after neoadjuvant chemotherapy (NACT) in patients undergoing interval debulking surgery (IDS) for advanced epithelial ovarian cancer (AEOC).Patients affected by...
Read MoreSHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathway.
Ovarian cancer caused the highest cancer-related mortality among female reproductive system malignancies. Platinum-based chemotherapy is still the footstone of the chemotherapy for ovarian cancer. However, the molecular...
Read MoreAdvertisement
Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen.
This study aimed to investigate exposure-response (ER) relationships in efficacy and safety for mirvetuximab soravtansine (MIRV) which is a first-in-class antibody-drug conjugate approved for the treatment of folate...
Read MoreRelevance of the common-sense model for people living with a genetic predisposition for breast and ovarian cancer.
BRCA1/2 pathogenic variants have been associated with an increased risk for breast, ovarian, pancreatic, prostate cancer as well as melanoma. The present research uses the Leventhal’s common-sense model of self-regulation...
Read MorePatient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways.
Malignant ascites is commonly produced in advanced epithelial ovarian cancer (EOC) and serves as unique microenvironment for tumour cells. Acellular ascites fluid (AAF) is rich in signalling molecules and has been proposed to...
Read MorePortal vein thrombosis and hepatic infarction due to hepatic mobilization after primary debulking surgery for advanced ovarian cancer: A case report.
Hepatic mobilization is essential in debulking surgery for resecting diaphragmatic lesions in advanced ovarian cancer. However, hepatic mobilization potentially induces postoperative portal vein thrombosis and hepatic...
Read More
MRG Prognostic Signature May Predict Survival Time of Patients With Ovarian Cancer
Ovarian cancer is a female-specific malignancy with high morbidity and mortality. The metabolic...
Read MoreCircular RNA circ_ARHGEF28 inhibits MST1/2 dimerization to suppress Hippo pathway to induce cisplatin resistance in ovarian cancer.
Cisplatin is integral to ovarian cancer treatment, yet resistance to this drug often results in adverse patient outcomes. The association of circular RNA (circRNA) with cisplatin resistance in ovarian cancer has been observed,...
Read More
Women With Endometriosis at Increased Risk for Ovarian Cancer
Women with endometriosis have an increased risk of ovarian cancer, with the highest risk seen for...
Read More
Early Menopause Tied to Heightened Risk for Breast and Ovarian Cancer
Women with early menopause have a two times greater risk for breast cancer and a nearly four times...
Read MoreTargeting PAX8 sensitizes ovarian cancer cells to ferroptosis by inhibiting glutathione synthesis.
Ovarian cancer is a malignant tumor originating from the ovary, characterized by its high mortality rate and propensity for recurrence. In some patients, especially those with recurrent cancer, conventional treatments such as...
Read More
Batiraxcept-Paclitaxel Combination Shows Promise in High AXL-Expressing, Platinum-Resistant Ovarian Cancer
Batiraxcept and paclitaxel as a combination therapy has shown significant results in improving progression free survival and overall rates.
Read More
Conjugated Equine Estrogen May Increase Risk for Ovarian Cancer
Conjugated equine estrogen (CEE) taken alone for menopause may increase the risk for developing...
Read More